ViroGates A/S Total Assets
ViroGates A/S total assets. Based on the latest financial reports, ViroGates A/S (VIRO) holds total assets worth Dkr26.77 Million DKK (≈ $4.19 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VIRO cash flow metrics for how efficiently the company converts equity into cash flow.
Total Assets of ViroGates A/S (2015–2025)
Total assets of ViroGates A/S from 2015 to 2025. This chart illustrates how ViroGates A/S's total assets have evolved over time, based on quarterly financial data. See ViroGates A/S (VIRO) stock price for real-time trading data and today's change.
ViroGates A/S - Asset Composition Analysis
ViroGates A/S Total Assets Breakdown (December 2025)
ViroGates A/S total assets breakdown as of December 2025. ViroGates A/S's total assets of Dkr26.77 Million consist of 99.4% current assets and 0.6% non-current assets. Explore VIRO working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 86.0% |
| Accounts Receivable | Dkr1.52 Million | 5.0% |
| Inventory | Dkr1.75 Million | 5.7% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how ViroGates A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ViroGates A/S's current assets represent 99.4% of total assets in 2025, an increase from 97.5% in 2015.
- Cash Position: Cash and equivalents constituted 86.0% of total assets in 2025, up from 83.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 5.7% of total assets.
ViroGates A/S Competitors by Total Assets
Key competitors of ViroGates A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SIEMENS HEALTH ADR/050
F:SHL1
|
Germany | €44.27 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Wellell Inc
TW:4106
|
Taiwan | NT$3.18 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €46.32 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
ViroGates A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.82 | 4.24 | 8.61 |
| Quick Ratio | 3.59 | 3.66 | 7.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr19.62 Million | Dkr12.10 Million | Dkr24.27 Million |
ViroGates A/S - Advanced Valuation Insights
This section examines the relationship between ViroGates A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.03 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 73.2% |
| Total Assets | Dkr30.59 Million |
| Market Capitalization | $10.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values ViroGates A/S's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ViroGates A/S's assets grew by 73.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ViroGates A/S (2015–2025)
The table below shows the annual total assets of ViroGates A/S from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr30.59 Million ≈ $4.79 Million |
+73.21% |
| 2024-12-31 | Dkr17.66 Million ≈ $2.76 Million |
-28.08% |
| 2023-12-31 | Dkr24.55 Million ≈ $3.84 Million |
+40.00% |
| 2022-12-31 | Dkr17.54 Million ≈ $2.74 Million |
-13.30% |
| 2021-12-31 | Dkr20.23 Million ≈ $3.16 Million |
-47.11% |
| 2020-12-31 | Dkr38.25 Million ≈ $5.98 Million |
-15.30% |
| 2019-12-31 | Dkr45.16 Million ≈ $7.07 Million |
-28.80% |
| 2018-12-31 | Dkr63.42 Million ≈ $9.92 Million |
+1174.07% |
| 2017-12-31 | Dkr4.98 Million ≈ $778.84K |
-58.51% |
| 2016-12-31 | Dkr12.00 Million ≈ $1.88 Million |
-31.11% |
| 2015-12-31 | Dkr17.41 Million ≈ $2.72 Million |
-- |
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more